A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors

Background Combinations of molecularly targeted agents may provide optimal anti-tumor activity and improve clinical outcomes for patients with advanced cancers. Selumetinib (AZD6244, ARRY-142886) is an oral, potent and highly selective, allosteric inhibitor of MEK1/2, a component of the RAS/RAF/MEK/...

Descripción completa

Detalles Bibliográficos
Autores principales: Infante, Jeffrey R., Cohen, Roger B., Kim, Kevin B., Burris, Howard A., Curt, Gregory, Emeribe, Ugochi, Clemett, Delyth, Tomkinson, Helen K., LoRusso, Patricia M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613062/
https://www.ncbi.nlm.nih.gov/pubmed/28424891
http://dx.doi.org/10.1007/s10637-017-0459-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613062/
https://www.ncbi.nlm.nih.gov/pubmed/28424891
http://dx.doi.org/10.1007/s10637-017-0459-7

Ejemplares similares